TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA

Latest FY: 2025 Healthcare Drug Manufacturers - Specialty & Generic
Market Price $36.77
Market Cap $42.48B
P/E Ratio 30.39
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑4.3% YoY
$17.26B
3-Yr CAGR: 5.0%
Net Income ↑186.0% YoY
$1.41B
Net Margin: 8.2%
Free Cash Flow ↑53.3% YoY
$1.15B
FCF Yield: 2.70%
EPS (Diluted) ↑183.4% YoY
$1.21
Basic: $1.23
Return on Equity Efficiency
17.8%
ROA: 10.1%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (TEVA)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $21,903.0M $11,859.0M $68.0M $0.07 $5,225.0M $4,324.0M
FY 2017 $22,385.0M +2.2% $10,615.0M $-16,265.0M -24,019.1% $-16.26 -23,328.6% $2,225.0M $1,351.0M -68.8%
FY 2018 $18,854.0M -15.8% $8,296.0M $-2,150.0M +86.8% $-2.35 +85.5% $2,446.0M $1,795.0M +32.9%
FY 2019 $16,887.0M -10.4% $7,537.0M $-999.0M +53.5% $-0.91 +61.3% $748.0M $223.0M -87.6%
FY 2020 $16,659.0M -1.4% $7,726.0M $-3,990.0M -299.4% $-3.64 -300.0% $1,216.0M $638.0M +186.1%
FY 2021 $15,878.0M -4.7% $7,594.0M $417.0M +110.5% $0.38 +110.4% $798.0M $236.0M -63.0%
FY 2022 $14,925.0M -6.0% $6,973.0M $-2,353.0M -664.3% $-2.12 -657.9% $1,590.0M $1,042.0M +341.5%
FY 2023 $15,846.0M +6.2% $7,645.0M $-559.0M +76.2% $-0.50 +76.4% $1,368.0M $842.0M -19.2%
FY 2024 $16,544.0M +4.4% $8,064.0M $-1,639.0M -193.2% $-1.45 -190.0% $1,247.0M $749.0M -11.0%
FY 2025 $17,258.0M +4.3% $8,938.0M $1,410.0M +186.0% $1.21 +183.4% $1,649.0M $1,148.0M +53.3%
$

Valuation

Market Price $36.77
Market Cap $42.48B
Enterprise Value N/A
P/E Ratio 30.39
P/B Ratio 5.41
FCF Yield 2.70%
Dividend Yield 0.00%
Shares Outstanding 1,164,426,972
%

Profitability & Margins

Gross Margin 51.79%
Operating Margin 12.50%
Net Margin 8.17%
Return on Equity (ROE) 17.83%
Return on Assets (ROA) 10.11%
Asset Turnover 1.24x
Revenue 3-Yr CAGR 4.96%
🛡️

Financial Health & Liquidity

Current Ratio 1.04
Cash Ratio 0.26
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $3.56B
Total Debt N/A
Book Value / Share $6.79
💧

Cash Flow Efficiency

Operating Cash Flow $1.65B
Capital Expenditures (CapEx) $501.00M
Free Cash Flow $1.15B
OCF / Revenue 9.55%
FCF / Revenue 6.65%
FCF 3-Yr CAGR 3.28%
🏷️

Per Share Metrics

EPS (Diluted) $1.21
EPS (Basic) $1.23
Dividends / Share N/A
Book Value / Share $6.79
EPS YoY Growth 183.45%
🏛️

Balance Sheet (FY 2025)

Total Assets $13.95B
Total Liabilities $13.46B
Stockholders' Equity $7.91B
Current Assets $13.95B
Current Liabilities $13.46B